Navigation Links
Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice
Date:10/23/2008

MONDAY, November 10, 2008 5:00 p.m. EST

HOPKINTON, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) will conduct a conference call discussing the company's third quarter 2008 financial results at 5:00 p.m. EST on Monday, November 10. Kevin Hrusovsky, President and Chief Executive Officer and Peter McAree, Chief Financial Officer, will host the call. Management will discuss operational and financial results and the company's outlook for the future.

A news release discussing Caliper's third quarter 2008 financial results will be issued Monday, November 10 at approximately 4:05 p.m. EST.

Participants please call 888.679.8034 five to ten minutes prior to the call and use the participant passcode of 71318859. International callers can access the call by dialing 617.213.4847 and entering the same passcode. You may also pre-register for the call at "https://www.theconferencingservice.com/prereg/key.process?key=P6E3NNKEA".

A live webcast of the call can be accessed at http://www.fulldisclosure.com or on the Caliper website at http://www.caliperLS.com in the Events section of the Investor Relations page. A webcast replay of the call will remain available until Caliper's earnings call for the fourth quarter of 2008.

Telephone replays of the conference call will be available approximately two hours after the completion of the call. To access a telephone playback of the proceedings from November 10 through November 17, dial 888.286.8010 and use the participant
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
2. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
3. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
4. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
5. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
6. Caliper Life Sciences Reports Second Quarter 2008 Results
7. Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice
8. Caliper Life Sciences Added to Russell 3000(R) Index
9. Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference
10. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... by Buffalo BioBlower Technologies LLC ("B3") as the critical ... 2 award from the Army Corps of Engineers.  B3 ... kills all biological contaminants and destroys VOCs and other ...
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... - Two Milestones Reached in Zonisamide Patent Portfolio ... Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... nervous system-related disorders, today,announced the initiation of its ... formulation of zonisamide plus olanzapine.,The Phase 2a clinical ...
... 2 Clarient, Inc.,(Nasdaq: CLRT ), a ... pathologists, oncologists and the pharmaceutical industry,today announced that ... an,exclusive interview on WallSt.net,s 3-Minute Press Show., ... company, and the,significance of the company,s latest press ...
... Zevalin only Radioimmunotherapy in U.S. to be Indicated ... for Use ... Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that it has ... and Drug,Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation ...
Cached Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:4/23/2014)... Valley, NY. (Apr. 23, 2014) People who have ... potential to restore neurological function. However, a study conducted ... issue of Cell Transplantation , but is currently ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group ... cells (PBSCs) injected directly into the brain and a ...
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... may begin in the womb, researchers from Tel Aviv University ... twin can compromise the health of his twin sister before ... published in the journal Pediatrics, the researchers analyzed the incidence ... twins. When born premature, girls who share the womb with ...
... A recent University of Iowa study reveals a biological link ... women than men are diagnosed with chronic pain and fatigue ... mice, the researchers, led by Kathleen Sluka, Ph.D., professor in ... the UI Roy J. and Lucille A. Carver College of ...
... 2008 The Global Innovation Imperatives (Gii) project ... their first session at the American Chemical Societys ... a joint collaboration between the ACS Committee on ... seeks to combat worldwide health, environmental and societal ...
Cached Biology News:War between the sexes begins before twins' birth, TAU researchers say 2U. Iowa study finds biological link between pain and fatigue 2At ACS' national meeting, global initiative set to tackle water issues 2
Request Info...
... blotted protein on PVDF membrane or with ... N-terminal sequence of proteins (5-20 residues) can ... HPLC or mono-and bidimensional SDS-PAGE, followed by ... the well known EDMAN degradation method. Pre-treatment ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
... 5 ml Dynabeads® (4.5 ... BerEP4 against the human epithelial ... molecule). Also available in ... 10e7 MNC in 1 ml ...
Biology Products: